Used in pharmaceutical synthesis as a key intermediate for kinase inhibitors, particularly in targeted cancer therapies. Its boronic ester functionality enables Suzuki-Miyaura cross-coupling reactions, allowing efficient construction of biaryl structures found in active pharmaceutical ingredients. Commonly employed in the development of tyrosine kinase inhibitors due to the quinazoline core’s affinity for ATP-binding sites in enzymes involved in tumor growth and proliferation. Also utilized in medicinal chemistry research for rapid analog generation and structure-activity relationship studies.